Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection

Miyamoto, Noriyuki; Hiramatsu, Kazuhide; Tsuchiya, Kunihiko; Sato, Yuki; Terae, Satoshi; Shirato, Hiroki

doi:10.1007/s11604-009-0317-4

Cited by 32 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CE-US with Sonazoid could provide valuable clinical information for planning RFA treatment protocols and was reported to be a useful procedure for assessing the efficacy of RFA of HCC (19). Evaluation of the local recurrence with CE-US is comparable to CE-MDCT which is one of the commonly used modalities for assessing the safety margin after treatment of HCC with RFA (20).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Contrast-Enhanced Ultrasonography in Radiofrequency Ablation for Hepatocellular Carcinoma

et al. 2012

View full text Add to dashboard Cite

Objective Local recurrence after radiofrequency ablation (RFA) is a major problem that needs to resolved to increase the survival rate of hepatocellular carcinoma (HCC). CE-US with Sonazoid , the secondgeneration contrast media, can detect smaller HCC lesions and the detection rate of ultrasonically unrecognized hypervascular HCC was improved by CE-US. The aim of the present study was to evaluate the role of CE-US with Sonazoid in improving radicality and reducing local recurrence after RFA for HCC. Patients and Methods A total of 102 nodules treated by RFA at our hospital from January 2006 to October 2009 were enrolled: 31 nodules were treated without CE-US, since CE-US was not yet available (Group A), and 71 nodules were treated with a combination of RFA and CE-US with Sonazoid (Group B). Results The clinical characteristics (sex, virus marker, Child-Pugh grade, with or without transcatheter arterial infusion chemotherapy with lipiodol, and T factor) did not differ significantly between group A and group B. Mean age was significantly older and tumor size was significantly larger in group B. Group B had significantly better radicality compared with group A. The non-local recurrence rate was significantly higher in group B as compared with group A. Conclusion CE-US with Sonazoid greatly helps to improve RFA efficacy in HCC treatment. We suggest that the ability of CE-US with Sonazoid to detect an accurate area of HCC before RFA and to immediately detect a residual tumor during RFA might contribute to an increase of the radicality and reduction of local recurrence after RFA.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Contrast-Enhanced Ultrasonography in Radiofrequency Ablation for Hepatocellular Carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, the recent advances of contrast media for ultrasonography, particularly Sonazoid, facilitated accurate pinpoint treatment guidance by Kupffer-phase and subsequent defect reperfusion imaging through reinjection [38,39,40]. This is really a major breakthrough [40,41,42,43,44,45]. …”

Section: Advances Of Techniques For Rfa Difficult Casesmentioning

confidence: 99%

Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010

Kudo

2010

Oncology

126

View full text Add to dashboard Cite

Percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) was introduced in Japan in 1999. It has been established as a main local treatment method worldwide including Japan. On comparing outcomes between resection and RFA, they were comparable when cases were limited to those with 3 or fewer tumors 3 cm or smaller in many reports, based on which RFA has become the main treatment for small HCCs. The 5-year survival rate following RFA was as high as 57% in patients registered in the Liver Cancer Study Group of Japan, 73% when cases were limited to liver damage A (Child-Pugh A), and 83.8 and 76.3% in liver damage A (Child-Pugh A) cases with a single 2-cm or smaller and 2- to 5-cm liver tumor, respectively, showing outcomes equivalent to those of resection. The outcomes at our facility were also favorable: the 5-year survival rates of Child-Pugh A liver function HCC cases with 3 or fewer tumors 3 cm or smaller following RFA and resection were 84 and 78%, respectively. Various complications and limitations of RFA have previously been reported, but the advances of physicians’ skills and development of various techniques have reduced complications and expanded the indications for RAF. TACE-combined, artificial pleural effusion- and ascites-combined, and contrast-enhanced ultrasonography-guided RFAs are good examples. Adjuvant therapy, such as interferon and molecular targeted therapies following curative therapy, is expected to further improve survival after RFA.

show abstract

“…To date, five prospective studies [20,21,22,23,24], two retrospective analyses [25,26] and one prospective randomized trial [27] have been published on this theme. Four studies report on the use of Levovist [20,21,26,27], three on Sonazoid [22,23,24] and only one on SonVue [25]. The latter study included patients with liver metastases as well [25].…”

Section: Targeting Hccmentioning

confidence: 99%

“…Harmonic gray-scale CEUS targeting emerges from the published literature as a highly sensitive and effective image-guiding tool, proving a consistent detection rate of 75–100% [20,21,22,23,24,26,27] (table 2). The detection rate is lower than 93% in only two studies [21,26].…”

Section: Targeting Hccmentioning

confidence: 99%

See 1 more Smart Citation

Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular Carcinoma

Andreana

Kudo²,

Hatanaka³

et al. 2010

Oncology

View full text Add to dashboard Cite

Most hepatocellular carcinomas (HCC) are diagnosed in patients with cirrhosis and/or when tumor burden is too advanced for surgical treatment. In many of these cases the only suitable therapy is locoregional, percutaneous and/or intraarterial treatment. Moreover, the best way to guide and assess response to locoregional HCC treatment are two issues under discussion today. First-generation and subsequent second-generation microbubble contrast agents, together with contrast-enhanced ultrasound (US) imaging, have expanded the role of US techniques in HCC treatments. In this review our purpose is to illustrate the advantages, limits and potential of contrast-enhanced US application for locoregional HCC treatment.

show abstract

Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection

Abstract: Sonazoid-enhanced sonography is a useful technique for guiding RF ablation of HCCs, even when treating local progression of a previously treated HCC.

Cited by 32 publications

References 31 publications

Efficacy of Contrast-Enhanced Ultrasonography in Radiofrequency Ablation for Hepatocellular Carcinoma

Efficacy of Contrast-Enhanced Ultrasonography in Radiofrequency Ablation for Hepatocellular Carcinoma

Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010

Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular Carcinoma

Contact Info

Product

Resources

About